Clinical utility of platelet count as a prognostic marker for melioidosis

Philippa Kirby, Simon Smith, Linda Ward, Josh Hanson, Bart J. Currie

Research output: Contribution to journalArticlepeer-review

25 Downloads (Pure)


Thromobocytopenia predicts mortality in patients with melioidosis in Thailand. We analyzed platelet counts in two large cohorts of melioidosis patients in tropical northern Australia to assess utility in a different clinical setting. Admission platelet counts were compared between subgroups of patients with different clinical outcomes. Patients with more severe disease (indicated by bacteremia, septic shock, and death) had significantly lower platelet counts than those with less severe disease. Logistic regression analysis was carried out for potential predictors of mortality among various clinical parameters, and platelet count was shown to be an independent predictor of mortality. Furthermore, in patients critically ill with melioidosis, an increasing platelet count after admission was associated with a significantly greater chance of survival. However, given that most patients with severe disease still had platelet counts within the normal range, platelet count is not a useful biomarker for predicting the severity of melioidosis in a clinical context.
Original languageEnglish
Pages (from-to)1085-1087
Number of pages3
JournalThe American Journal of Tropical Medicine and Hygiene
Issue number5
Early online date18 Mar 2019
Publication statusPublished - 1 May 2019


Dive into the research topics of 'Clinical utility of platelet count as a prognostic marker for melioidosis'. Together they form a unique fingerprint.

Cite this